The Nobel Prize-winning technology underpinning COVID-19 vaccines is also fueling a host of biotechs developing treatments ...

Palivizumab injection (Synagis), an RSV prevention therapy for children, is being discontinued and will no longer be available as of December 31, 2025.

“We’ve stepped back into the world that we lived in before the [CDC’s vaccine advisory committee] was created,” said Dr.

The Food and Drug Administration is considering pulling its authorization of Pfizer’s COVID-19 vaccine for healthy children ...

Pfizer Inc (($PFE)) announced an update on their ongoing clinical study. Pfizer Inc. is conducting a study titled Retrospective Study Evaluating ...

A new study shows that while RSV mostly affects younger kids, the often-overlooked human metapneumovirus also hospitalizes ...

Respiratory syncytial virus vaccine uptake was low among older veterans, with disparities observed across demographic and social risk factors.

Biotechnology company Moderna (NASDAQ:MRNA) announced better-than-expected revenue in Q2 CY2025, but sales fell by 41.1% year ...

U.S. Health and Human Services Secretary Robert F. Kennedy Jr. announced last week that his department would slash about $500 ...

Moderna may offer substantial upside, but it's essential to consider the associated risks. Since hitting their peak in late ...